Integer Holdings Corp
NYSE:ITGR
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
I
|
Integer Holdings Corp
NYSE:ITGR
|
3B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
189.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
137.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
135.6B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
133.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.7B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.6B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.7B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Integer Holdings Corp
Glance View
Integer Holdings Corporation, a prominent player in the medical device industry, has carved a significant niche by aligning innovation with robust manufacturing capabilities. Founded as a collaborative effort between technical ingenuity and healthcare innovation, Integer primarily engages in the design and production of medical devices and components that are instrumental for the med-tech sector. It serves a diverse clientele that ranges from large healthcare conglomerates to emerging med-tech companies. The company operates through two main segments: Medical and Non-Medical. In the Medical division, Integer excels by providing critical components used in cardiac rhythm management, neuromodulation, and vascular access. It thrives on the premise that precision in manufacturing and innovation are key to producing reliable and effective medical solutions, ensuring that they meet stringent regulatory standards. What truly propels Integer’s financial engine is its commitment to operational excellence and strategic partnerships. By integrating vertically across its production processes, Integer achieves cost efficiencies that allow it to offer competitive pricing without sacrificing quality. Moreover, the company extends its influence through strategic partnerships with prominent healthcare providers, thereby securing long-term contracts and steady revenue streams. This model is supplemented by its Non-Medical segment, where Integer provides high-reliability components for energy, military, and environmental applications. These ventures not only diversify its revenue portfolio but also bolster its resilience against market volatility. Integer’s growth narrative is underscored by a relentless focus on research and development, which facilitates continuous product enhancement and keeps it at the forefront of technological advancement in the medical device industry. Through these strategies, Integer Holdings Corporation not only sustains its market position but also expands its role as a critical enabler in the global healthcare landscape.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Integer Holdings Corp is 4.7%, which is below its 3-year median of 5.5%.
Over the last 3 years, Integer Holdings Corp’s Net Margin has decreased from 5.5% to 4.7%. During this period, it reached a low of 4.5% on Mar 28, 2025 and a high of 7% on Dec 31, 2024.